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toringAbstract Introduction: Administration of the most appropriate dose of chemotherapy to
neonates is particularly challenging and frequently not standardised based on any scientific
rationale. We report the clinical utility of carboplatin therapeutic drug monitoring in preterm
and full-term neonates within the first month of life.
Methods: Carboplatin therapeutic monitoring was performed to achieve target drug expo-
sures area under the plasma concentration–time curve (AUC values) in nine preterm and
full-term neonates diagnosed with retinoblastoma or neuroblastoma treated over an 8 year
period. Carboplatin was administered over 3 days with therapeutic drug monitoring utilised
to target cumulative AUC values of 5.2–7.8 mg/ml min.
Results: AUC values achieved were within 15% of target values for the individual courses of
treatment in all but one patient (12/13 courses of treatment), with dose modifications of up to
215% required to achieve target AUC values, based on initial mg/kg dosing schedules.
Carboplatin clearance determined across three consecutive chemotherapy courses in two
patients increased from 3.4 to 7.1 ml/min and from 7.2 to 16.5 ml/min, representing increaseswcastle
G.J. Veal et al. / European Journal of Cancer 51 (2015) 2022–2030 2023of 210–230% over several weeks of treatment. Complete remission was observed in 8/9
patients, with no renal toxicity reported and only one patient experiencing ototoxicity.
Conclusion: The study highlights the benefits of utilising therapeutic drug monitoring to
achieve target carboplatin AUC values in preterm and full-term neonates treated within the
first few weeks of life, particularly in view of marked increases in drug clearance observed over
consecutive chemotherapy courses. In the absence of therapeutic drug monitoring,
body-weight based dosing is recommended, with dosing guidance provided for both
approaches to inform future treatment.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CCBY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The treatment of cancer in very young children repre-
sents a major clinical challenge. Developmental physio-
logical changes within the first few weeks of birth have
the potential to markedly impact drug disposition, mak-
ing selection of the most appropriate dosing regimen
particularly difficult [1–4]. While dose reductions are
commonplace for the vast majority of anticancer drugs
utilised in infants and very young children, with reduced
dosing regimens commonly defined as being applicable
below a specific age or body weight, these dose reduc-
tions are largely defined for children between 3 and
12 months of age [5]. The treatment of preterm and
full-term neonates in the first few weeks of life needs
to be approached judiciously, with the aim of achieving
meaningful drug levels to exhibit anti-tumour efficacy,
but without adversely affecting the developing child.
A key challenge in this area is the limited amount of
data available concerning anticancer drug disposition in
the neonatal patient population. However, for those
drugs where studies have been reported, clearance values
have frequently been shown to differ markedly from
those seen in older children and adults [6]. Indeed, this
is not surprising when we consider the continuing devel-
opment and maturation of renal and hepatic function
within the first few weeks of life, which may significantly
impact on drug metabolism and elimination [7,8]. The
generation of an increased volume of drug disposition
data in this patient population is essential if we are
to positively impact on the treatment of preterm and
full-term neonates with cancer through the provision of
meaningful dosing regimens based on ‘real world’ data.
The platinum agent carboplatin represents one of rel-
atively few anticancer drugs where information gathered
from clinical pharmacology studies has directly
impacted on its clinical use in children with cancer. As
removal of carboplatin from the body occurs almost
exclusively via elimination of unchanged drug in the
urine, initial doses are commonly based on renal func-
tion as defined by the glomerular filtration rate (GFR)
of the patient [9,10]. In addition, exposure to carbo-
platin is commonly targeted to a defined area under
the plasma concentration–time curve (AUC), which
has been shown to more closely correlate with clinicalparameters including toxicity and response than the
dose administered [11,12].
Based on our current knowledge of the pharmacol-
ogy of carboplatin, changes in kidney function are
highly likely to impact on drug disposition. At birth
renal function is anatomically and functionally imma-
ture, with marked increases during the first 2 weeks of
life due to changes in renal vascular resistance and active
nephrogenesis occurring between 9 and 36 weeks from
birth, with accompanying changes in renal blood flow
[13,14]. GFR values of 2–4 ml/min/1.73 m2 are com-
monly observed in full-term neonates, with values as
low as 0.6–0.8 ml/min/1.73 m2 in preterm neonates
[14,15]. While the kidney of the newborn is sufficient
for normal growth and development, it provides limited
adjustment to a stressful catabolic state which may be
observed in sick preterm infants [16]. These changes with
advancing gestational and postnatal age provide real
potential for differences in drug clearance to be observed
in neonates as compared to older children. In this
respect we previously published a case report of a pre-
term infant treated with carboplatin, highlighting the
potential for marked changes in drug clearance with
age and requirement for increasing doses of carboplatin
to achieve defined target AUC values [17].
In the current study we report on the wider clinical
utility of carboplatin therapeutic drug monitoring in
nine preterm and full-term neonates being treated for
retinoblastoma and low risk neuroblastoma within the
first weeks of life. Publication of these data in a small
but significant patient population allow us to provide
clear guidance for clinicians which will positively impact
on the future treatment of preterm and full-term neo-
nates with carboplatin. This is clearly an important issue
considering a recent report that younger children are at
an increased risk of experiencing ototoxicity following
treatment with carboplatin [18].
2. Patients and methods
2.1. Patient treatment
Nine preterm and full-term neonates, studied over an
8 year period, received carboplatin treatment at six clin-
ical centres as part of their standard treatment. Patients
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neonates) or gestational ages of 52 weeks (born at
28 weeks), 35 weeks (born at 32 weeks) and 36 weeks
(born at 29 weeks) for preterm neonates, and had been
diagnosed with retinoblastoma (seven patients) or low
risk neuroblastoma (two patients), one stage 4s with
massive hepatomegaly and respiratory compromise
and one localised, unresectable without segmental chro-
mosomal abnormalities presenting with spinal cord
compression. Patient information is provided alongside
details of individual patient treatment in Table 1. It
should be noted that patient 001 was more than 4 weeks
of age (52 weeks post-menstrual age) at the time of treat-
ment and therefore falls outside the strict definition of a
neonate. In all cases carboplatin was administered
diluted in 5% dextrose as a 60 min intravenous infusion.
Initial doses were based on body weight or body surface
area, with therapeutic drug monitoring approaches used
to achieve target carboplatin AUC values whereTable 1
Patient characteristics and treatment details.
Patient Tumour type Age at
diagnosis
Initial treatment and
carboplatin dosing regi
001 Retinoblastoma
(bilateral)
52 weeks
gestational age
(born at
28 weeks)
Single agent carboplatin
100 mg/m2/day 3; tar
AUC 5.2 mg/ml mina,d
002 Retinoblastoma
(bilateral)
3 days
(gestational age
of 40 weeks)
Single agent carboplatin
target AUC 5.8 mg/ml
003 Neuroblastoma
(low risk stage 4s)
2 weeks
(gestational age
of 37 weeks)
Carboplatin (6.6 mg/kg
etoposide (5 mg/kg)
004 Neuroblastoma
(low risk,
localised, un-
resectable)
3 days
(gestational age
of 40 weeks)
Carboplatin (4.4 mg/kg
etoposide (5 mg/kg)
005 Retinoblastoma
(bilateral)
35 weeks
gestational age
(born at
32 weeks)
Single agent carboplatin
(6.6 mg/kg); target AU
5.2 mg/ml mina
006 Retinoblastoma
(bilateral)
3 weeks
(gestational age
of 40 weeks)
JOEb 6 cycles; carbop
dose 100 mg/m2/day 3
target AUC 7.7 mg/ml
007 Retinoblastoma
(left)
1 week
(gestational age
of 40 weeks)
JOEb 3 cycles; carbop
dose 6.6 mg/kg/day 3
target AUC 7.8 mg/ml
008 Retinoblastoma
(bilateral)
36 weeks
gestational age
(born at
29 weeks)
Single agent carboplatin
target AUC 5.2 mg/ml m
009 Retinoblastoma
(right)
3 weeks
(gestational age
of 40 weeks)
Single agent carboplatin
(6.6 mg/kg) to target A
5.8 mg/ml min a
TDM – therapeutic drug monitoring.
a Patient also received local laser treatment.
b JOE – vincristine, etoposide and carboplatin.
c Patient also received thermotherapy.
d Patient also received cryotherapy.required. Ethical approval was not required for this
approach to treatment which is classed as the most
appropriate clinical practice based on current evidence.
Therapeutic drug monitoring in this setting was carried
out at the request of the treating clinician.
2.2. Blood sampling and analysis
Blood samples (1 ml) for pharmacokinetic analysis
were obtained from a central line before carboplatin
infusion, 30 min after the start of infusion, at 60 min
(end of infusion) and at 120–180 min after the start
of infusion (60–120 min post-infusion). Plasma was
separated from whole blood samples by centrifugation
(1200g, 4 C, 10 min), and 0.5 ml was then removed
and placed in an Amicon Centrifree micropartition unit
with a 30,000 MW cut-off (Millipore, Edinburgh, UK).
This sample was centrifuged (1500g, 4 C, 15 min) to
obtain plasma ultrafiltrate for the determination of freemen
Number of
courses of
carboplatin
TDM approach taken
get
6 TDM used to achieve target AUC on course 1.
Good response and tolerability so equivalent
mg/kg dosing used for courses 2–6
to
mina
6 TDM used to achieve target AUCs on courses
1/2. Good response after courses 1 and 2 so
equivalent mg/m2 dosing used for courses 3–6
)/ 1 TDM proposed to determine AUC achieved
on course 1
)/ 2 TDM used to determine AUCs achieved on
courses 1 and 2. Good response and
tolerability following mg/kg dosing on both
courses
C
5 TDM used to achieve target AUC on courses
1–3. Good response and tolerability so
equivalent mg/kg dosing used for courses 4/5
latin
;
min
4 TDM used to achieve target AUC on course 1.
Good response and tolerability so equivalent
mg/m2 dosing used for courses 2–4
latin
;
minc
3 TDM used to achieve target AUCs on courses
1/2. Good response and tolerability so
equivalent mg/kg dosing used for course 3
to
in a
3 TDM used to achieve target AUC on courses
1–3
UC
2 TDM used to achieve target AUC on courses
1 and 2
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courier, on dry ice and in an insulated container, to
the Northern Institute for Cancer Research,
Newcastle University. Platinum pharmacokinetic anal-
yses were carried out by flameless atomic absorption
spectrophotometry (AAS) using a Perkin–Elmer
AAnalyst 600 graphite furnace spectrometer
(Perkin-Elmer Ltd, Beaconsfield, UK). Free or
unbound platinum levels were determined in plasma
ultrafiltrates as described previously [19,20]. All sam-
ples were analysed in duplicate and values expressed
as the average of these measurements. Duplicate values
were within 15% of each other in all cases. Intra- and
inter-assay coefficients of variation for a quality assur-
ance sample had to be <10% for an assay to be valid.
The limit of quantification (LOQ) for the AAS assay
was 0.10 lg/ml.
2.3. Therapeutic drug monitoring
Carboplatin clearance and AUC were determined by
Bayesian analysis following each dose of carboplatin
using a two compartment model as described previ-
ously [20,21]. In brief, this allows the reliable estima-
tion of carboplatin AUC through use of limited
sampling approaches, with carboplatin clearance and
AUC calculated based on data collected from previ-
ously studied paediatric patients aged 0–18 years. The
two compartment model used was fitted to individual
patient plasma ultrafiltrate concentrations determined
by AAS using the Bayesian maximum a posterior
(MAP) estimator and an error model derived from
the previously defined population error model parame-
ters. For patients being treated on a 3-day carboplatin
schedule, dosing was adjusted on either day 2 or day 3,
based on drug exposures and clearance values deter-
mined for day 1 and/or day 2, to achieve the desired
target cumulative AUC. Carboplatin dose adjustments
were recommended for all patients with day 1 (or days
1 and 2) AUC values >10% outside the target daily
AUC. Dose adjustments were calculated based on the
actual carboplatin clearance determined on day 1 (or
days 1 and 2) and the remaining AUC to be achieved.
Dosing on subsequent courses of carboplatin treatment
was guided by the exposures observed on course 1,
with therapeutic drug monitoring again carried out as
appropriate.
2.4. Statistical analysis
Linear regression analysis and the Pearson corre-
lation coefficient were used to indicate correlations
between actual patient body weight and carboplatin
clearance and between age and carboplatin
clearance.3. Results
3.1. Carboplatin treatment and dose adjustment
Patients received carboplatin either as single agent
treatment (5/9 patients) or with additional chemother-
apy including etoposide (4/9 patients) and vincristine
(2/9 patients) as shown in Table 1. Real-time therapeutic
drug monitoring approaches were used to either allow
the modification of carboplatin dosage over 3 days of
treatment to achieve a target cumulative AUC value,
or to determine the AUC value achieved with the dosing
regimen implemented, with a view to maintaining or
altering the target AUC for course 2 of treatment based
on the response and/or toxicity observed (as outlined in
Table 1). Target cumulative carboplatin AUC values
ranged from 5.2 to 7.8 mg/ml min over 3 days of treat-
ment. Carboplatin doses were modified in real-time
based on the daily AUC values observed in seven
patients. In an additional patient, confirmation of the
achievement of appropriate carboplatin AUC values,
alongside observable clinical responses, allowed doses
to be maintained on subsequent courses of treatment.
The final patient had an AUC value calculated on day
1 of treatment, with a view to modifying carboplatin
dosage on days 2/3, but died prior to treatment on
day 2 due to complications relating to the size and posi-
tion of the tumour (stage 4s neuroblastoma).
Initial doses of carboplatin administered on day 1 of
course 1 of treatment ranged from 3.5–6.6 mg/kg/day,
with day 1 AUC values of 0.8–2.7 mg/ml min achieved,
reflecting a sixfold range in carboplatin clearance values
of 3.4–19.4 ml/min. Cumulative AUC values calculated
on courses of carboplatin chemotherapy where blood
samples were collected were within 15% of the target
value for the individual courses of treatment in all but
one patient (12/13 courses of treatment), with dose mod-
ifications of up to 215% required to achieve target AUC
values, based on the initial mg/kg dosing schedule
implemented. The cumulative AUC achieved for patient
008 on course 2 of treatment was outside the desired
±15% AUC target window due to a shift in carboplatin
clearance between days 1 and 3. Predicted AUC values
that would have been achieved without the implementa-
tion of therapeutic drug monitoring were up to 100%
outside of the target AUC (ranging from 2.4 to
9.7 mg/ml min), based on the carboplatin clearance val-
ues observed on each day of treatment. Table 2 shows
the carboplatin doses administered and AUC values
achieved in each of the seven patients where doses were
modified in real-time over 3 day treatment periods,
based on the daily AUC values observed.
Table 3 provides a summary of carboplatin doses
administered and carboplatin clearance values observed
on course 1 (nine patients), courses 1 and 2 (six patients)
Table 2
Carboplatin doses administered and AUC values achieved on courses of treatment where therapeutic drug monitoring was used to adjust dosing as
compared to BW-based dosing approaches.
Patient Treatment
course
Target AUC
(mg/ml min)
Carboplatin dose
(mg)
AUC (mg/ml min)
Actual
(TDM)
BW-
baseda
Actual
(TDM)
BW-
basedb
001 1 5.2 80 78 5.2 5.1
002 1 5.8 105 72 5.8 3.9
2 7.8 136 120 7.8 6.8
005 1 5.2 15.5 33 5.0 9.7
2 7.8 38 36 7.1 6.4
3 7.8 55 44 7.7 6.2
006 1 7.7 71 75 7.3 7.8
007 1 7.8 80 60 6.4 4.8
008 1 5.2 43 21 6.1 2.9
2 7.8 70 29 7.8 3.2
3 7.8 129 39 7.8 2.4
009 1 5.8 63 63 5.8 5.8
2 5.8 90 78 8.2 7.1
TDM – therapeutic drug monitoring; BW – body weight.
a BW-based dosing regimens varied from 3.5 to 6.6 mg/kg/day depending on treatment centre and protocol used to guide initial treatment.
b BW-based AUC values are predicted from the carboplatin clearance values determined during treatment, reflecting the values that would have
been observed if BW-based dosing had been carried out.
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between patient body weight and carboplatin clearance
for all courses of chemotherapy where samples for phar-
macokinetic analysis were obtained (i.e. 17 courses
across nine patients), is shown in Fig. 1A. Similarly,
relationships between patient age (normalised to
full-term gestation for neonates born preterm) and car-
boplatin clearance, and between patient age (normalised
to full-term gestation for neonates born preterm) and
carboplatin clearance normalised to body weight are
shown in Fig. 1B and C, respectively. Carboplatin clear-
ance and AUC values were determined across three con-
secutive courses of chemotherapy in two patients, with
mean clearance values increasing from 3.4 to 7.1 ml/minTable 3
Carboplatin clearance values observed on courses 1–3 of treatment.
Patient Carboplatin course 1 Carboplatin course
BW
(kg)
SA
(m2)
Daily dose
(mg)
Cla
(ml/min)
BW
(kg)
SA
(m2)
D
(
001 4.1 0.26 26 15.5
002 3.7 0.25 24–41 18.5 4.5 4
003 3.5 0.24 15 19.4
004 3.6 15 14.1 3.9 0.26 1
005 1.6 4.5–11 3.4 2.3 1
006 4.0 0.26 23–25 9.6
007 3.2 20–30 12.7 3.6 3
008 2.0 0.16 7–18 7.2 2.8 0.20 1
009 3.2 0.21 21 11.0 3.9 0.26 2
BW – body weight; SA – surface area; Cl – clearance.
a Mean clearance values shown where carboplatin pharmacokinetics detein patient 005 and from 7.2 to 16.5 ml/min in patient
008, representing increases of 210% and 230%, respec-
tively (Fig. 2), over 7–8 weeks of treatment.
3.2. Treatment response and toxicity
Of the seven patients treated for retinoblastoma,
complete remission was observed in all cases following
2–6 courses of single agent carboplatin or in combina-
tion with the additional anticancer drugs and treatment
approaches outlined in Table 1. All of these patients
remain in remission with follow-up periods currently
ranging from 5 months to >5 years. One patient
relapsed on two separate occasions but now remains in2 Carboplatin course 3
aily Dose
mg)
Cla
(ml/min)
BW
(kg)
SA
(m2)
Daily dose
(mg)
Cla
(ml/min)
0 17.6
7 14.6
1–16 5.6 2.7 15–20 7.1
0 12.0
8 9.0 3.8 0.20 25 16.5
6–38 11.0
rmined on more than one day of a particular course of treatment.
Fig. 1. Relationship between patient body weight and carboplatin
clearance (A), between patient age (normalised to full-term gestation
for preterm neonates) and carboplatin clearance (B) and between
patient age (normalised to full-term gestation for preterm neonates)
and carboplatin clearance (normalised to body weight) (C).
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platin, etoposide and vincristine alongside local laser
treatment. Grade 3/4 haematological toxicities including
neutropenia and anaemia were observed in 4/7 patients
with retinoblastoma, with additional toxicities including
diarrhoea, vomiting and a septic episode. Only one
patient experienced ototoxicity in the form of sen-
sorineuronal deafness and in this case it was unclear to
what extent this was attributable to carboplatin treat-
ment as the patient had pre-existing hearing loss andassociated 13q deletion syndrome. No patients studied
experienced renal toxicity.
One patient with low risk, localised, unresectable
neuroblastoma experienced a complete response after
two courses of carboplatin treatment and subsequent
spontaneous tumour regression. No significant toxicity
including renal or hearing impairment was observed
and the patient remains disease free with 5 year
follow-up. The second patient with low risk, stage 4s
neuroblastoma died prior to carboplatin treatment on
day 2 of the first course of treatment due to complica-
tions relating to tumour burden.4. Discussion
The limited knowledge of drug disposition in preterm
and full-term neonates for the vast majority of anti-
cancer drugs means that defining appropriate dosing
regimens for this patient population is a challenging
task. The current study provides real world data which
for the first time facilitates the provision of
scientifically-based dosing guidelines for the treatment
of preterm and full-term neonates with carboplatin.
The incidence of ototoxicity in children treated with car-
boplatin has previously been highlighted as a major con-
cern, with incidence rates of carboplatin-induced
ototoxicity ranging from 8 to 50% across various
tumour types [18,22–24]. In this respect, a recently pub-
lished study by Qaddoumi et al. highlighted the fact that
younger children with retinoblastoma are at an
increased risk of experiencing ototoxicity, with children
<6 months of age 21-times more likely to have sustained
hearing loss than older children following carboplatin
treatment [18]. Indeed, in this study 9/10 of patients
who experienced sustained hearing loss were between
0.4 and 4.5 months of age at the time of treatment, as
compared to an age range of 0.5 months to 13.6 years
in 50 patients who experienced no hearing loss; with
median ages of 2.3 versus 10.3 months in these two
groups respectively [18].
The data presented in the current study highlight the
benefits of utilising therapeutic drug monitoring to tar-
get carboplatin AUC values, with achieved AUC values
within 15% of the target on 12/13 courses where this
approach was instigated. This allowed for the achieve-
ment of cumulative AUC values of 5.0–8.2 mg/ml min,
based on a target AUC range of 5.2–7.8 mg/ml min, as
opposed to a range of 2.9–9.7 mg/ml min which would
have been achieved if no therapeutic drug monitoring
had been implemented. In addition to the possibility
that reduced carboplatin dosing implemented in neo-
nates based on therapeutic drug monitoring may have
resulted in the avoidance of toxicity in some of these
patients, it is also important to consider the potential
clinical impact of dose increases in those patients with
lower drug exposures prior to drug monitoring.
Fig. 2. Change in carboplatin clearance values measured across three courses of treatment in two patients.
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observed most notably in this study in the case of
patients 002 and 008, not only avoid potential gross
under-treatment, but may also help to negate an inaccu-
rate judgement of chemo-insensitivity and resultant
change to second line treatments which may be less effec-
tive and more toxic.
The range of initial carboplatin dosing approaches
taken by different UK clinical centres on day 1 of treat-
ment for this patient population highlights the uncer-
tainties that exist and the lack of guidance available to
treating clinicians. While in older children doses of car-
boplatin are frequently based on GFR, this is not possi-
ble within the first few days and weeks of life,
predominantly due to the fact that radioactive and con-
trast media markers utilised for GFR measurement are
not recommended for use in neonates by most clinicians.
In addition, the collection of 24 h urine samples is not
feasible in neonates and the interpretation of results
can be difficult. Initial doses were therefore predomi-
nantly based on BW-based or BSA-based dosing, with
doses ranging from 3.5 to 6.6 mg/kg/day or 100 to
200 mg/m2. While therapeutic monitoring over 3 days
of treatment largely negates the differences in initial dos-
ing regimens in the patients included in the current
study, it is important to analyse the data generated
appropriately in order to provide rational dosing guide-
lines to be utilised when therapeutic drug monitoring
approaches are not possible.
Based on the relatively good correlation observed
between patient BW and carboplatin clearance,
BW-based dosing would appear to be the most pertinent
approach to recommend in the absence of therapeutic
drug monitoring. This is supported by previously pub-
lished studies which have investigated the impact of var-
ious factors on renal function maturation in neonates
and identified weight as the best standard for prediction
of GFR [25,26]. In addition, data from several clinical
trials have raised concerns over the use of BSA-baseddosing as compared to BW-based dosing in infants with
retinoblastoma [18,27,28]. In terms of an appropriate
dose for treatment, we have generally utilised an initial
target AUC value of 5.2 mg/ml min for the first course
of treatment. Clinicians have then either opted to main-
tain this target AUC on additional courses of treatment,
or have opted to increase the dose to target an AUC of
7.8 mg/ml min, depending on the response and level of
toxicity observed. This will of course depend on whether
or not carboplatin is being used alone or whether there
are other chemotherapeutics being used in combination
which need to be considered. Based on a median AUC
of 1.325 mg/ml min being equivalent to a dose of
3.3 mg/kg, as used to develop the original carboplatin
paediatric dosing formula by Newell et al. [12], we
would recommend an initial starting dose of 4.4
mg/kg/day for 3 days of treatment on course 1, equivalent
to a target AUC of 5.2 mg/ml min. This can be increased
to a dose of 6.6 mg/kg/day for 3 days of treatment on
course 2 if this was felt likely to be beneficial, based
on the observed response and toxicity following course
1. Similarly, these guidelines do not preclude further
dose increases above 6.6 mg/kg/day being employed
where lack of response and toxicity is observed at this
dose. In the current study the equivalent mg/kg/day dos-
ing regimens required to obtain target AUC values of
5.2 and 7.8 mg/ml min were 3.2–7.2 mg/kg/day and
5.5–13 mg/kg/day respectively, therefore clearly some
patients required higher doses for the achievement of
these target exposures. Fig. 3 provides a carboplatin
dosing guidance flow diagram for the treatment of pre-
term and full-term neonates with retinoblastoma, based
on the data generated in the current study.
When considering the results obtained in the current
study, it is important to consider children with neurob-
lastoma and retinoblastoma in the neonatal period as
distinct populations, each with its own unique issues.
In the neuroblastoma population, there is a potentially
life-threatening condition that has a risk of causing
Fig. 3. Carboplatin dosing guidance flow diagram for the treatment of retinoblastoma in preterm and full-term neonates up to 3 weeks of age.
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ing induction chemotherapy, but where response to
treatment and long-term outcome after initial treatment
are very good. As long-term chemotherapy treatment is
unlikely to be needed, the aim of treatment in this sce-
nario is to save the life of the neonate, while avoiding
life-threatening complications with limited cycles of
treatment. The population with retinoblastoma has the
potential for life-threatening illness, but the major issue
is preservation of sight without compromising the excel-
lent chance of cure or causing co-morbidities. In this sit-
uation treatment is likely to be prolonged and may need
to be repeated, with the aim of administering an appro-
priate amount of chemotherapy to control the disease,
while limiting potentially long-term side-effects such as
ototoxicity.
In summary, we would recommend that carboplatin
therapeutic drug monitoring approaches are utilised in
preterm and full-term neonates whenever feasible, par-
ticularly bearing in mind the marked increases in carbo-
platin clearance observed over several courses of
treatment. While allometric scaling with BW to anexponent of 0.75 or BSA represent appropriate
approaches for the achievement of comparable expo-
sures across a wide age range for many drugs,
BSA-based dosing would not be appropriate for
carboplatin due to its reliance on renal clearance and
the disproportionally low GFR observed in infants. As
observed carboplatin AUC values are highly variable
even with BW-based dosing, therapeutic drug monitor-
ing should be recommended. Such approaches may be
particularly relevant in the case of neonates with
retinoblastoma, where treatment within the first few
weeks or months of life may lead to an increased risk
of visual defects following treatment [29,30]. In this clin-
ical scenario it is clearly important to reduce the possi-
bility of sensorineural hearing loss, which is likely to
have an even greater impact on the quality of life of a
child who also has visual impairment. However, we
appreciate that therapeutic drug monitoring approaches
will not be possible in many cases. The guidance pro-
vided in relation to the use of BW-based dosing to target
the equivalent of AUC values of 5.2–7.8 mg/ml min
reflects the most appropriate approach to dosing based
2030 G.J. Veal et al. / European Journal of Cancer 51 (2015) 2022–2030on currently available data. It is essential that while con-
tinuing to ensure positive clinical outcomes in patients
being treated with cytotoxic anticancer drugs such as
carboplatin, we also strive to minimise the side-effects
of treatment. The current study uses evidence from
pre-term and full-term neonates treated with carboplatin
in the first few weeks of life to provide dosing guidance
which will positively impact on the treatment of future
patients.
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